Landmark Trial: Perioperative Apalutamide Improves Metastasis-Free Survival in Localized High-Risk Prostate Cancer

For more than a decade, the standard of care for high-risk localized prostate cancer has remained stubbornly static, leaving a critical gap in long-term outcomes. While radical prostatectomy—the surgical removal of the prostate—offers a chance at a cure, up to 50 percent of patients with high-risk features experience a relapse within five years.[5]

When the disease returns and spreads, the prognosis darkens considerably. The medical community has long sought a way to intensify treatment early, striking the cancer before it can establish microscopic footholds elsewhere in the body.[2][5]

Now, the final analysis of the Phase 3 PROTEUS trial has delivered a definitive breakthrough. Presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New England Journal of Medicine, the data demonstrates that a "perioperative" approach—administering systemic therapy both before and after surgery—significantly improves survival and delays relapses.[1][2]

The trial tested the addition of apalutamide (marketed as Erleada), a next-generation androgen receptor pathway inhibitor, to standard androgen deprivation therapy (ADT). Prostate cancer cells rely on androgens, like testosterone, to grow and multiply.[1][4]

While standard ADT lowers the overall levels of testosterone in the body, apalutamide works by binding directly to the androgen receptors on the cancer cells themselves, effectively starving the tumor of the fuel it needs to survive and proliferate.[4][5]

The PROTEUS trial enrolled 2,109 patients across 18 countries, making it the largest therapeutic trial in localized high-risk prostate cancer in 13 years. Participants were randomly assigned to receive either apalutamide plus ADT or a placebo plus ADT.[2][3]

The treatment regimen was intensive: patients took the oral medication for six months prior to their radical prostatectomy, and then resumed the regimen for another six months following the surgery.[4]

The first major piece of evidence emerged in the pathology lab. When surgeons removed the prostates, pathologists examined the tissue to measure the "pathologic complete response" or "minimal residual disease"—essentially, how much cancer was left after the initial six months of drug therapy.[1][5]

The results were stark. Patients receiving the apalutamide combination were approximately nine times more likely to have little to no cancer remaining in the prostate at the time of surgery. Specifically, 8.9 percent of the apalutamide group achieved this near-total clearance, compared to just 1.0 percent of the placebo group.[2][3][4]

However, shrinking the primary tumor is only half the battle; the ultimate goal is preventing the cancer from metastasizing to the bones or other organs. The PROTEUS trial tracked metastasis-free survival (MFS) over a median follow-up period of 61.7 months.[5]

The data confirmed that the early pathological success translated into long-term clinical benefits. The apalutamide regimen reduced the overall risk of metastasis or death by 20 percent compared to hormone therapy alone.[1][2]

At the five-year mark, an estimated 78.2 percent of patients in the apalutamide arm remained alive and free of metastasis, compared to 73.5 percent in the control arm. Furthermore, the treatment reduced the risk of any oncologic event or death by 29 percent.[2][4]

Perhaps the most profound quality-of-life metric in the study was the delay in subsequent therapies. When prostate cancer recurs, patients are typically subjected to salvage radiation or indefinite courses of systemic drugs, which carry compounding side effects.[5]

Patients treated with the perioperative apalutamide regimen experienced a massive delay before needing any additional treatment. The median time to subsequent therapy was 74.2 months for the apalutamide group, compared to 41.5 months for the placebo group.[2][3]

This nearly three-year extension means that, on average, patients enjoyed a five-year treatment-free interval after completing their initial one-year course of apalutamide—a window of normal life that is highly prized by patients and their families.[2][5]

Despite the overwhelmingly positive data, the trial did highlight areas of clinical nuance and transparent uncertainty. During the study's multi-year run, highly sensitive PSMA-PET imaging became the new standard for detecting prostate cancer spread, replacing older, less precise bone scans.[2][3]

Because PSMA-PET scans can spot microscopic metastases much earlier, they triggered subsequent therapies sooner for some patients in the trial. This "stage migration" slightly complicated the statistical analysis of conventional imaging, though the overall survival benefit remained robust across independent reviews.[3][5]

Additionally, surgical urologists caution against a blanket application of the intensive regimen. Not all high-risk prostate cancers behave identically, and some patients with favorable high-risk features may still be cured by surgery alone, raising valid concerns about overtreatment and the financial toxicity of adding a year of expensive targeted therapy.[2][5]

The safety profile of the combination was consistent with the known side effects of apalutamide, which can include fatigue, hypertension, and skin rashes. Physicians will need to weigh these risks against the profound survival advantages on a case-by-case basis.[2][4]

Ultimately, the PROTEUS trial marks a paradigm shift. By proving that combining systemic targeted therapy with surgery can eradicate microscopic disease and extend survival, the study establishes a new standard of care, bringing prostate cancer treatment in line with the aggressive, multi-modal strategies already used to conquer breast and lung cancers.[1][5]